Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College.
Sanjay qualified from Guy’s and St Thomas’ Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.
He is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. His research interests include identification and validation of biomarkers that influence thoracic tumour development and treatment, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.
He Chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he leads the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG).
et al., 2022, Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment, Jama Network Open, Vol:5, ISSN:2574-3805
et al., 2022, Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer, Cell Reports Medicine, Vol:3, ISSN:2666-3791
et al., 2022, Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naive and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1), European Journal of Cancer, Vol:174, ISSN:0959-8049, Pages:S75-S76
et al., 2022, Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla (TM) EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib' Not looking back, European Journal of Cancer, Vol:174, ISSN:0959-8049, Pages:318-320
et al., 2022, Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+advanced non-small cell lung cancer (NSCLC), European Journal of Cancer, Vol:174, ISSN:0959-8049, Pages:S1-S2